Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 10:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Behavioral intervention + placebo Clear all
Completed Phase 2 Interventional Results available

Targeted Interventions for Weight-Concerned Smokers

NCT00105482
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Naltrexone, Transdermal nicotine replacement, Behavioral counseling
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 28, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Results available

Modafinil Combined With Cognitive Behavior Therapy to Treat Cocaine Addiction - 1

NCT00218387
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Modafinil, Matching Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 28, 2026, 10:08 AM EDT
Terminated Phase 2 Interventional Results available

A Folinic Acid Intervention for Autism Spectrum Disorders

NCT01602016
View directory record Official record
Conditions
Autism Spectrum Disorder, Autistic Disorder, Autism, Asperger's Syndrome, Pervasive Development Disorders
Interventions
Folinic Acid and placebo, Folinic Acid
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
3 Years to 14 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 28, 2026, 10:08 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity

NCT06009653
View directory record Official record
Conditions
Obesity, Metabolic Disease
Interventions
Standard Care, Culturally-tailored dietary and behavioral intensive lifestyle intervention, Placebo, Tirzepatide
Behavioral · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 28, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Results available

Improving Therapeutic Learning in Depression: Proof of Concept

NCT02376257
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
250 mg DCS, 100 mg Modafinil, Placebo
Drug
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 28, 2026, 10:08 AM EDT
Completed Phase 2 Interventional

Indirect Assessment and Intervention for Perinatal Drug Use

NCT01650675
View directory record Official record
Conditions
Drug Abuse
Interventions
WIDUS computer-delivered, indirect brief intervention, Nutrition time control/placebo intervention
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Sep 28, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Antidepressants in Chronic Back Pain

NCT00964886
View directory record Official record
Conditions
Back Pain
Interventions
cognitive behavioral therapy, desipramine hydrochloride, benztropine mesylate 0.125 mg daily
Behavioral · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 28, 2026, 10:08 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer

NCT01628029
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Sleep Disorder
Interventions
Counseling, Methylphenidate Hydrochloride, Phototherapy, Placebo Administration, Quality-of-Life Assessment, Sham Intervention, Therapeutic Melatonin
Other · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 28, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Results available

Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder

NCT00383786
View directory record Official record
Conditions
PTSD
Interventions
NK1 Antagoist (GR205171), Psychophysiology (Trauma Script), Psychophysiology (Verbal Threat), Psychophysiology (Fear Conditioning), Psychophysiology (Affective Modulation), Psychophysiology (Heart rate variability), Lumbar Puncture, 24-hour plasma sampling, MRI
Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Sep 28, 2026, 10:08 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children

NCT00178503
View directory record Official record
Conditions
Autism, Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate-extended release, Methylphenidate-immediate release, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
7 Years to 12 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2013 · Synced Sep 28, 2026, 10:08 AM EDT
Completed Phase 4 Interventional

Solriamfetol and CBT-I in Patients With Insomnia Disorder

NCT05838430
View directory record Official record
Conditions
Insomnia
Interventions
Solriamfetol 75 MG, Cognitive Behavioral Therapy for Insomnia (CBT-I), Monitoring, Placebo
Drug · Behavioral · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
25 Years to 60 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 28, 2026, 10:08 AM EDT
Recruiting Phase 3 Interventional

Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder

NCT07123467
View directory record Official record
Conditions
Generalized Anxiety Disorder (GAD), Anxiety Disorders
Interventions
Low-Dose Cannabidiol, Placebo Matched to Moderate-Dose Cannabidiol, Moderate-Dose Cannabidiol, Placebo Matched to Low-Dose Cannabidiol
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 28, 2026, 10:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder

NCT00399763
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Substance Abuse
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
12 Years to 19 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Sep 28, 2026, 10:08 AM EDT
Completed Not applicable Interventional

Pushing Behaviors in Individuals Post-stroke

NCT02190734
View directory record Official record
Conditions
Stroke
Interventions
Sitting in wheel chair, Gait training on treadmill, Gait training overground
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 89 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Honolulu, Hawaii • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2019 · Synced Sep 28, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Results available

Effect of D-cycloserine on Treatment of Posttraumatic Stress Disorder (PTSD) in Youth

NCT01157416
View directory record Official record
Conditions
Posttraumatic Stress Disorders, PTSD
Interventions
D-cycloserine, Placebo pill, CBT
Drug · Behavioral
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
7 Years to 12 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 28, 2026, 10:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

CBT With Disulfiram and Contingency Management

NCT00350870
View directory record Official record
Conditions
Cocaine Abuse
Interventions
disulfiram, Placebo, Placebo plus Contingency Management, Disulfiram plus Contingency Management
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Sep 28, 2026, 10:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Continuation of The Kronos Early Estrogen Prevention Study (KEEPS)

NCT03718494
View directory record Official record
Conditions
Alzheimer Dementia
Interventions
Brain Magnetic Resonance Imaging (MRI), F-18 Florbetapir Positron Emission Tomography (PET) Imaging, F-18 AV-1451 Positron Emission Tomography (PET) Imaging, Neuropsychological Testing
Diagnostic Test · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
49 Years to 72 Years · Female only
Enrollment
299 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
6
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 28, 2026, 10:08 AM EDT
Terminated Phase 3 Interventional Results available

Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes

NCT02856581
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Varenicline, Placebo, Tobacco Cessation Counseling
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
374
States / cities
Fairbanks, Alaska • Kingman, Arizona • Jonesboro, Arkansas + 236 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 28, 2026, 10:08 AM EDT
Completed Phase 3 Interventional

Pharmacological Treatment for Alcoholism

NCT00382642
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Ondansetron + Cognitive Behavioral Therapy, Placebo + Cognitive Behavioral Therapy
Drug
Lead sponsor
Bankole Johnson
Other
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Sep 28, 2026, 10:08 AM EDT
Completed Phase 2 Interventional

Pioglitazone as an Adjunct to Cognitive-Behavioral Therapy for Cocaine Relapse Prevention

NCT04843046
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Cognitive Behavioral Therapy (CBT), Pioglitazone, Placebo
Behavioral · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 28, 2026, 10:08 AM EDT
Terminated Phase 2 Interventional Results available

Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1

NCT03507127
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 28, 2026, 10:08 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Nicotine Patch Pretreatment for Smoking Cessation in PTSD

NCT00625131
View directory record Official record
Conditions
Stress Disorders, Posttraumatic, Tobacco Use Disorder
Interventions
Nicotine, Cognitive Behavioral Therapy for Smoking Cessation, Bupropion Sustained Release (SR), Placebo patch
Drug · Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Sep 28, 2026, 10:08 AM EDT
Completed Not applicable Interventional Results available

Virtual Reality & D-cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)

NCT00632632
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
D-Cycloserine, Placebo
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Sep 28, 2026, 10:08 AM EDT
Completed Phase 4 Interventional Results available

DECIFER: Depression and Citalopram In First Episode Recovery

NCT01041274
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder
Interventions
Citalopram, Placebo, Psychoeducation, Cognitive Behavioral Therapy (CBT), Functional Magnetic Resonance Imaging (fMRI)
Drug · Behavioral · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 40 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 28, 2026, 10:08 AM EDT